Zac-Varghese, S;
Mark, P;
Bain, S;
Banerjee, D;
Chowdhury, TA;
Dasgupta, I;
De, P;
Fogarty, D;
Frankel, A;
Goldet, G;
et al.
Zac-Varghese, S; Mark, P; Bain, S; Banerjee, D; Chowdhury, TA; Dasgupta, I; De, P; Fogarty, D; Frankel, A; Goldet, G; Karalliedde, J; Mallik, R; Montero, R; Sharif, A; Wahba, M; Dhatariya, K; McCafferty, K; Lioudaki, E; Winocour, P
(2024)
Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.
BMC Nephrol, 25 (1).
p. 216.
ISSN 1471-2369
https://doi.org/10.1186/s12882-024-03664-1
SGUL Authors: Banerjee, Debasish
Abstract
The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk factor and good lipid management offers improved outcomes for people with diabetic kidney disease (DKD).The primary purpose of this guideline, written by the Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) working group, is to provide practical recommendations on lipid management for members of the multidisciplinary team involved in the care of adults with DKD.
Item Type: |
Article
|
Additional Information: |
Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
Keywords: |
Chronic kidney disease, Diabetes, Diabetic kidney disease, Lipid management, Lipids, Nephropathy, Humans, Diabetic Nephropathies, Adult, United Kingdom, Cardiovascular Diseases, Lipids, Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Humans, Diabetic Nephropathies, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Adult, United Kingdom, Diabetic kidney disease, Lipid management, Diabetes, Lipids, Chronic kidney disease, Nephropathy, 1103 Clinical Sciences, Urology & Nephrology |
SGUL Research Institute / Research Centre: |
Academic Structure > Institute of Medical & Biomedical Education (IMBE) |
Journal or Publication Title: |
BMC Nephrol |
ISSN: |
1471-2369 |
Language: |
eng |
Dates: |
Date | Event |
---|
6 July 2024 | Published | 1 July 2024 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
PubMed ID: |
38971750 |
Web of Science ID: |
WOS:001263389300001 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/116711 |
Publisher's version: |
https://doi.org/10.1186/s12882-024-03664-1 |
Statistics
Item downloaded times since 30 Jul 2024.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |